Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 51 of 57 for:    Romidepsin | Phase 2

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03161223
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : May 15, 2019
Sponsor:
Collaborators:
University of Bologna
Samsung Medical Center
Celgene
Information provided by (Responsible Party):
Owen A, O'Connor, M.D., Ph.D., Columbia University

Brief Summary:

This is an open-label, Phase 1/2a, dose-finding study with an initial phase 1 portion, articulated in four separate treatment arms, followed by a dedicated phase 2 for qualifying treatment Arm(s).

The primary objective of the Phase 1 portion is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of: Durvalumab, oral 5-azacitidine, and romidepsin (Arm A); durvalumab, pralatrexate, and romidepsin (Arm B); durvalumab and romidepsin (Arm C); or durvalumab and oral 5-azacitidine (Arm D), in patients with peripheral T-cell lymphoma (PTCL). The safety and toxicity profile of these combinations will be evaluated throughout the entire study.

If one or more of the combinations in Arms A, B, C, or D are found to be feasible and an MTD is established, the phase 2 portion of the study will be initiated for the combination(s) with the strongest efficacy signal provided acceptable toxicity.


Condition or disease Intervention/treatment Phase
Lymphoma, T-Cell Drug: Durvalumab Drug: Pralatrexate Drug: Romidepsin Drug: 5-Azacitidine Phase 1 Phase 2

Detailed Description:
The peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive lymphoid neoplasms and account for 10-15% of all newly diagnosed cases of non-Hodgkin's lymphoma (NHL). The current prevalence of PTCL in the United States is estimated to be approximately 9,500 patient. Treatment options for patients with relapsed/refractory (R/R) PTCL have been limited. This study focuses on exploring rational combinations of these T-cell active agents in an effort to develop novel treatment platforms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 148 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Phase 1 A minimum of 3 patients will be treated at the entry Dose Level, that is the MTD, in each arm. An estimated 10 patients will be accrued in each Arm, assuming ≤ 1 patients experience DLT. If a DLT is reached early we will treat fewer patients. For each study Arm, we will expand the MTD cohort to a total of 10 patients. We estimate that a total of 40 patients will be needed.

Phase 2 Once the recommended phase 2 dose is identified, a planning meeting with the Sponsor and involved investigators will be convened to discuss which Arm(s) to advance to phase 2. The sample size of the phase 2 portion of the study will be calculated on an optimal 2-stage design. We will first enroll 8 patients. If at least 3 objective responses (PR or CR) are seen, then an additional 16 patients will be enrolled. If 10 or fewer patients respond, the combination will not be considered for further study. We will enroll a total of 24 patients per arm.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2a Study of the Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Azacitidine and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine Alone for the Treatment of Patients With Relapsed and Refractory Peripheral T-Cell Lymphoma
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2021


Arm Intervention/treatment
A: Oral 5-azacitidine, durvalumab, romidepsin
Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
Drug: Durvalumab

Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).

Starting dose: 1500 mg

Other Name: MEDI4736

Drug: Romidepsin

Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).

Starting dose: 12 mg/m2

Other Name: Depsipeptide

Drug: 5-Azacitidine

Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).

Starting dose: 300 mg daily

Other Names:
  • Vidaza
  • Oral 5-Azacitidine

B: durvalumab, pralatrexate, romidepsin
Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
Drug: Durvalumab

Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).

Starting dose: 1500 mg

Other Name: MEDI4736

Drug: Pralatrexate

Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).

Starting dose: 25 mg/m2

Other Name: Folotyn

Drug: Romidepsin

Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).

Starting dose: 12 mg/m2

Other Name: Depsipeptide

C: durvalumab, romidepsin
Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
Drug: Durvalumab

Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).

Starting dose: 1500 mg

Other Name: MEDI4736

Drug: Romidepsin

Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).

Starting dose: 12 mg/m2

Other Name: Depsipeptide

D: durvalumab, 5-azacitidine
Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
Drug: Durvalumab

Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).

Starting dose: 1500 mg

Other Name: MEDI4736

Drug: 5-Azacitidine

Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).

Starting dose: 300 mg daily

Other Names:
  • Vidaza
  • Oral 5-Azacitidine




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: 1 year ]
    The highest dose of study treatment that does not cause unacceptable side effects in patients with R/R PTCL in each study arm


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 1 year ]
    ORR will be defined as the sum of complete response rate and partial response rate based on evaluation of best response in each patient.

  2. Duration of Response (DoR) [ Time Frame: 1 year ]
    Time from documentation of tumor response to disease progression

  3. Progression Free Survival (PFS) [ Time Frame: 1 year ]
    Time from study treatment until disease progression or death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (these criteria apply to both the phase 1 and phase 2 portion of the study)

  • Age >18 years at the time of signing the informed consent
  • Patients must have histologically confirmed ND or R/R PTCL defined according to the 2016 World Health Organization (WHO) classification criteria.
  • Patients with R/R PTCL who have received at least one previous line of therapy are eligible to be enrolled in this study.
  • Patients who are candidate for an autologous or allogeneic SCT will be allowed to receive the study drugs as a "bridge" to transplantation.
  • Evaluable (phase 1) or measurable (phase 2) disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Patients must have adequate organ and marrow function as defined by:

    1. Aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2 x institutional upper limit of normal (ULN); total bilirubin ≤ 1.5 x ULN (AST, ALT, and total bilirubin ≤ 3 × ULN in subjects with documented Gilbert's syndrome or hyperbilirubinemia clearly attributed to lymphoma involvement of the liver);
    2. Creatinine levels < 2 mg/dL; or creatinine clearance > 40 mL/min
    3. Absolute neutrophil count (ANC) > 1,000/μL; platelet count > 75,000/μL
    4. Negative urine or serum pregnancy test for women of childbearing potential. All women of childbearing potential must agree to use an effective barrier method of contraception (either an IUD or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month after discontinuation of the study drugs. Male subjects should use effective barrier method of contraception during the treatment period and for at least 3 months after discontinuation of the study drugs.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Ability to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria (these criteria apply to both the phase 1 and phase 2 portion of the study)

  • Prior Therapy (for patients with R/R PTCL)

    1. Exposure to any agent targeting PD-1, PD-L1 or CTLA-4.
    2. For three-drug combinations, the patient must not have been exposed to at least two of those drugs. For two drugs combinations patients must not have been exposed to any of those drugs. Patients will be enrolled in the first treatment Arm that satisfies this exclusion criterion, according to the following sequence: Arm A; Arm B; Arm C; Arm D.
    3. Exposure to biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation therapy within 2 weeks prior to entering the study or lack of resolution of AE due to previously administered antineoplastic therapy to grade 1 or less according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
    4. Current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab. The following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10 mg/day of prednisone or equivalent for at least 5 days prior to the start of the study drugs.
    5. Prior allogeneic SCT
  • History of, or suspected allergic reactions to, durvalumab, pralatrexate, oral 5-azacitidine, or romidepsin or any of their excipients.
  • For patients who are treated with oral 5-azacitidine, any gastrointestinal disorder that would interfere with the absorption of the study drug
  • Concomitant use of CYP3A4 inhibitors
  • Uncontrolled intercurrent illness.
  • Any of the following cardiac abnormalities (only for patients receiving romidepsin):

    1. Congenital long QT syndrome;
    2. QTc interval ≥ 501 milliseconds;
    3. Patients taking drugs leading to significant QT prolongation (See Appendix 3);
    4. Myocardial infarction within 6 months of cycle 1, day 1. [Subjects with a history of myocardial infarction between 6 and 12 months prior to cycle 1, day 1, who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event, may participate];
    5. Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min);
    6. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
    7. An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ≥ 2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
    8. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 5) and/or ejection fraction < 40% by multitargeted acquisition (MUGA) scan or < 50% by echocardiogram and/or magnetic resonance imaging (MRI);
    9. A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
    10. Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes;
    11. Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or
    12. Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers).
  • Pregnancy or breast-feeding.
  • Active concurrent malignancy (except non-melanoma skin cancer, prostatic intraepithelial neoplasia, or carcinoma in situ of the cervix). Patients whose lymphoma has transformed from a less aggressive histology remain eligible.
  • Receipt of solid organ transplant.
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: subjects with vitiligo or alopecia; subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; or subjects with psoriasis not requiring systemic treatment.
  • CNS involvement, including lymphomatous meningitis.
  • Known active hepatitis A, B or C virus infection.
  • Known HIV infection.
  • History of primary immunodeficiency.
  • Receipt of live, attenuated vaccine within 30 days prior to study entry. Enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumab.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161223


Contacts
Layout table for location contacts
Contact: Michelle Malanga, MPA 212-326-5731 mm4629@cumc.columbia.edu

Locations
Layout table for location information
United States, New York
Center for Lymphoid Malignancies at CUMC Recruiting
New York, New York, United States, 10019
Contact: Michelle Malanga, MPA         
Principal Investigator: Owen A O'Connor, M.D., PhD         
Sub-Investigator: Jennifer E Amengual, M.D.         
Sub-Investigator: Ahmed Sawas, M.D.         
Sub-Investigator: Changchun Deng, M.D.         
Sub-Investigator: Lorenzo Falchi, M.D.         
Italy
University of Bologna Not yet recruiting
Bologna, Italy
Principal Investigator: Pier Luigi Zinzani, M.D., PhD.         
Korea, Republic of
Samsung Medical Center Not yet recruiting
Seoul, Korea, Republic of
Principal Investigator: Won Seog Kim, M.D., Ph.D.         
Sponsors and Collaborators
Columbia University
University of Bologna
Samsung Medical Center
Celgene
Investigators
Layout table for investigator information
Principal Investigator: Owen A O'Connor, M.D., PhD Columbia University School of Medicine

Layout table for additonal information
Responsible Party: Owen A, O'Connor, M.D., Ph.D., Professor of Medicine at the Columbia University Medical Center, Dept of Med Hematology & Onc, Columbia University
ClinicalTrials.gov Identifier: NCT03161223     History of Changes
Other Study ID Numbers: AAAR0365
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: May 15, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Romidepsin
Lymphoma
Lymphoma, T-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antibodies, Monoclonal
Azacitidine
Aminopterin
Durvalumab
Immunologic Factors
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Folic Acid Antagonists